Compare Adobe Systems Inc (ADBE) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Neurocrine Biosciences Inc — how do they compare? Adobe Systems Inc trades at $263.57 (market cap $108.50B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Adobe Systems Inc is far larger — about 6.5× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | NBIX | |
|---|---|---|
Market Cap | $108.50B | $16.76B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $185.50 |
52-Week Low | $193.41 | $123.10 |
Enterprise Value | $109.94B | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $272.96, up 2.92% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $5.96 exceeding the $5.82 estimate. Revenue grew to $23.77B in 2025, and net income margin improved to 28.69%. However, the stock faces headwinds from AI competition fears and a recent 52-week low, as noted by Citi on April 10, 2026.
The outlook is mixed: robust fundamentals and a 49.2% buy rating from analysts support upside potential, with a consensus price target of $248.86. Key risks include generative AI disruption and CEO transition uncertainty. Investors should weigh strong cash flows against competitive pressures in the software sector.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
